ERBB2 and neoplasm: Since we found that changes in the HER2 status in recurrent tumours compared to primary tumours were particularly frequent in patients with HER2-negative and HER-low primary tumours, we compared main clinical and pathological characteristics of primary HER2-negative BCs stratified by the HER2 status change pattern between the primary and recurrent tumour (stable or not).